C4 Therapeutics stock rises on Roche deal

C4 Therapeutics experienced a notable stock price increase following the announcement of an expanded partnership with Roche. This collaboration focuses on the development of novel cancer therapies, leveraging C4 Therapeutics' expertise in targeted protein degradation. The expanded agreement signifies increased confidence from Roche in C4's pipeline and technology. Investors reacted positively to the news, anticipating potential advancements in oncology treatments and the financial benefits associated with a strengthened relationship with a major pharmaceutical company. The deal is expected to accelerate drug development efforts.